Prognostic Value of Cardiovascular Biomarkers in the Population
JAMA · 11.06.2024 · 331 (22) · 1898
DOI: 10.1001/jama.2024.5596 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 11.06.2024. Verfasst von Johannes Tobias Neumann und 53 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Biomarkers, Cardiovascular Diseases, Natriuretic Peptide, Brain, Peptide Fragments. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Importance Identification of individuals at high risk for atherosclerotic cardiovascular disease within the population is important to inform primary prevention strategies.
Objective
To evaluate the prognostic value of routinely available cardiovascular biomarkers when added to established risk factors. Design, Setting, and Participants Individual-level analysis including data on cardiovascular biomarkers from 28 general population–based cohorts from 12 countries and 4 continents with assessments by participant age. The median follow-up was 11.8 years. Exposure Measurement of high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, B-type natriuretic peptide, or high-sensitivity C-reactive protein. Main Outcomes and Measures The primary outcome was incident atherosclerotic cardiovascular disease, which included all fatal and nonfatal events. The secondary outcomes were all-cause mortality, heart failure, ischemic stroke, and myocardial infarction. Subdistribution hazard ratios (HRs) for the association of biomarkers and outcomes were calculated after adjustment for established risk factors. The additional predictive value of the biomarkers was assessed using the C statistic and reclassification analyses.
Results
The analyses included 164 054 individuals (median age, 53.1 years [IQR, 42.7-62.9 years] and 52.4% were women). There were 17 211 incident atherosclerotic cardiovascular disease events. All biomarkers were significantly associated with incident atherosclerotic cardiovascular disease (subdistribution HR per 1-SD change, 1.13 [95% CI, 1.11-1.16] for high-sensitivity cardiac troponin I; 1.18 [95% CI, 1.12-1.23] for high-sensitivity cardiac troponin T; 1.21 [95% CI, 1.18-1.24] for N-terminal pro-B-type natriuretic peptide; 1.14 [95% CI, 1.08-1.22] for B-type natriuretic peptide; and 1.14 [95% CI, 1.12-1.16] for high-sensitivity C-reactive protein) and all secondary outcomes. The addition of each single biomarker to a model that included established risk factors improved the C statistic. For 10-year incident atherosclerotic cardiovascular disease in younger people (aged <65 years), the combination of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein resulted in a C statistic improvement from 0.812 (95% CI, 0.8021-0.8208) to 0.8194 (95% CI, 0.8089-0.8277). The combination of these biomarkers also improved reclassification compared with the conventional model. Improvements in risk prediction were most pronounced for the secondary outcomes of heart failure and all-cause mortality. The incremental value of biomarkers was greater in people aged 65 years or older vs younger people. Conclusions and Relevance Cardiovascular biomarkers were strongly associated with fatal and nonfatal cardiovascular events and mortality. The addition of biomarkers to established risk factors led to only a small improvement in risk prediction metrics for atherosclerotic cardiovascular disease, but was more favorable for heart failure and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Center for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
- Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
- Center for Cardiometabolic Disease Prevention, Department of Medicine, College of Medicine, Baylor University, Houston, Texas.
- Department of Medicine, Boston Medical Center, Chobanian and Avedisian School of Medicine, Boston University, Boston, Massachusetts.
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
Zitieren
APA
Neumann, J. T., Twerenbold, R., Weimann, J., Ballantyne, C. M., Benjamin, E. J., Costanzo, S., de Lemos, J. A., deFilippi, C. R., Di Castelnuovo, A., Donfrancesco, C., Dörr, M., Eggers, K. M., Engström, G., Felix, S. B., Ferrario, M. M., Gansevoort, R. T., Giampaoli, S., Giedraitis, V., Hedberg, P., …, & Ojeda, F. (2024). Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA, 331(22), 1898. https://doi.org/10.1001/jama.2024.5596
Vancouver
Neumann JT, Twerenbold R, Weimann J, Ballantyne CM, Benjamin EJ, Costanzo S, et al. Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024;331(22):1898. doi:10.1001/jama.2024.5596
BibTeX
@article{Neumann2024,
author = {Neumann, Johannes Tobias and Twerenbold, Raphael and Weimann, Jessica and Ballantyne, Christie M and Benjamin, Emelia J and Costanzo, Simona and de Lemos, James A and deFilippi, Christopher R and Di Castelnuovo, Augusto and Donfrancesco, Chiara and Dörr, Marcus and Eggers, Kai M and Engström, Gunnar and Felix, Stephan B and Ferrario, Marco M and Gansevoort, Ron T and Giampaoli, Simona and Giedraitis, Vilmantas and Hedberg, Pär and Iacoviello, Licia and Jørgensen, Torben and Kee, Frank and Koenig, Wolfgang and Kuulasmaa, Kari and Lewis, Joshua R and Lorenz, Thiess and Lyngbakken, Magnus N and Magnussen, Christina and Melander, Olle and Nauck, Matthias and Niiranen, Teemu J and Nilsson, Peter M and Olsen, Michael H and Omland, Torbjorn and Oskarsson, Viktor and Palmieri, Luigi and Peters, Anette and Prince, Richard L and Qaderi, Vazhma and Vasan, Ramachandran S and Salomaa, Veikko and Sans, Susana and Smith, J Gustav and Söderberg, Stefan and Thorand, Barbara and Tonkin, Andrew M and Tunstall-Pedoe, Hugh and Veronesi, Giovanni and Watanabe, Tetsu and Watanabe, Masafumi and Zeiher, Andreas M and Zeller, Tanja and Blankenberg, Stefan and Ojeda, Francisco},
title = {Prognostic Value of Cardiovascular Biomarkers in the Population},
journal = {JAMA},
year = {2024},
volume = {331},
number = {22},
pages = {1898},
doi = {10.1001/jama.2024.5596}
}
EUVIMED